Trends in Use of Antiseizure Medication and Treatment Pattern During the First Trimester in the German Embryotox Cohort

Overview

Journal Sci Rep

Specialty Science

Date 2024 Dec 23

PMID 39715780

Authors

Maria Hoeltzenbein

Sofia Slimi

Anne-Katrin Fietz

Katarina Dathe

Christof Schaefer

Affiliations

Soon will be listed here.

Abstract

Because of their developmental toxicity, some antiseizure medication (ASM) should be avoided during pregnancy. This may lead to discontinuation or switching of ASM after recognition of pregnancy, but some of these changes may be suboptimal. Trends in ASM use at conception were analyzed in 3,763 pregnancies prospectively ascertained by a teratology information service in Germany between 2000 and 2018. Focusing on women with epilepsy (n = 2,395), changes of treatment pattern during the 1st trimester were evaluated. There was an increase in women using ASMs for non-epilepsy indications from 19% in 2000 to 39% in 2018. Although a shift from non-recommended teratogenic ASMs to recommended ASMs was observed, 13% of women were still receiving non-recommended ASMs in early pregnancy at the end of the study period. Among women with epilepsy, ASM regimen remained unchanged during the 1st trimester in 90%, 6% switched to other ASMs, and only 4% discontinued. Valproate, oxcarbazepine, and topiramate were more likely to be discontinued or switched than other ASMs. This first analysis of treatment pattern in ASM exposed pregnancies in Germany confirms the general trend towards less teratogenic and newer ASMs. However, it remains questionable whether women still using non-recommended ASMs are refractory to lower-risk ASMs or disregard treatment guidelines and risk minimization measures.

References

Tomson T, Battino D, Bromley R, Kochen S, Meador K, Pennell P . Executive Summary: Management of epilepsy in pregnancy: A report from the International League Against Epilepsy Task Force on Women and Pregnancy. Epilepsia. 2019; 60(12):2343-2345. DOI: 10.1111/epi.16395. View

Abtahi S, Pajouheshnia R, Duran C, Riera-Arnau J, Gamba M, Alsina E . Impact of 2018 EU Risk Minimisation Measures and Revised Pregnancy Prevention Programme on Utilisation and Prescribing Trends of Medicinal Products Containing Valproate: An Interrupted Time Series Study. Drug Saf. 2023; 46(7):689-702. PMC: 10252161. DOI: 10.1007/s40264-023-01314-3. View

Skorpen C, Hoeltzenbein M, Tincani A, Fischer-Betz R, Elefant E, Chambers C . The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. Ann Rheum Dis. 2016; 75(5):795-810. DOI: 10.1136/annrheumdis-2015-208840. View

Li Y, Meador K . Epilepsy and Pregnancy. Continuum (Minneap Minn). 2022; 28(1):34-54. PMC: 9642109. DOI: 10.1212/CON.0000000000001056. View

Amrhein V, Greenland S, McShane B . Statistical significance gives bias a free pass. Eur J Clin Invest. 2019; 49(12):e13176. DOI: 10.1111/eci.13176. View

Cohen J, Cesta C, Furu K, Einarsdottir K, Gissler M, Havard A . Prevalence trends and individual patterns of antiepileptic drug use in pregnancy 2006-2016: A study in the five Nordic countries, United States, and Australia. Pharmacoepidemiol Drug Saf. 2020; 29(8):913-922. DOI: 10.1002/pds.5035. View

Anmella G, Vieta E . Teratogenicity of valproate: Further reasons for action. Eur Neuropsychopharmacol. 2023; 80:25-26. DOI: 10.1016/j.euroneuro.2023.11.008. View

Herzog A, Mandle H, Cahill K, Fowler K, Hauser W . Predictors of unintended pregnancy in women with epilepsy. Neurology. 2017; 88(8):728-733. DOI: 10.1212/WNL.0000000000003637. View

Hoeltzenbein M, Bartz I, Fietz A, Lohse L, Onken M, Dathe K . Antiepileptic treatment with levetiracetam during the first trimester and pregnancy outcome: An observational study. Epilepsia. 2023; 65(1):26-36. DOI: 10.1111/epi.17800. View

10.

Hoeltzenbein M, Beck E, Fietz A, Wernicke J, Zinke S, Kayser A . Pregnancy Outcome After First Trimester Use of Methyldopa: A Prospective Cohort Study. Hypertension. 2017; 70(1):201-208. DOI: 10.1161/HYPERTENSIONAHA.117.09110. View

11.

Vajda F, OBrien T, Graham J, Hitchcock A, Perucca P, Lander C . The teratogenesis risk associated with antiseizure medication duotherapy in women with epilepsy. Epilepsy Res. 2024; 200:107316. DOI: 10.1016/j.eplepsyres.2024.107316. View

12.

Schaefer C, Ornoy A, Clementi M, Meister R, Weber-Schoendorfer C . Using observational cohort data for studying drug effects on pregnancy outcome--methodological considerations. Reprod Toxicol. 2008; 26(1):36-41. DOI: 10.1016/j.reprotox.2008.05.064. View

13.

Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M . 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension: The Task Force for the management of.... J Hypertens. 2018; 36(10):1953-2041. DOI: 10.1097/HJH.0000000000001940. View

14.

Vajda F, Dodd S, Horgan D . Lamotrigine in epilepsy, pregnancy and psychiatry--a drug for all seasons?. J Clin Neurosci. 2012; 20(1):13-6. DOI: 10.1016/j.jocn.2012.05.024. View

15.

Houben E, Benson R, Steegers E, Herings R . Twenty-year trends in the use of anti-seizure medication among pregnant women in the Netherlands. Epilepsy Behav. 2022; 127:108549. DOI: 10.1016/j.yebeh.2021.108549. View

16.

Hernandez-Diaz S, Mittendorf R, Smith C, Hauser W, Yerby M, Holmes L . Association between topiramate and zonisamide use during pregnancy and low birth weight. Obstet Gynecol. 2014; 123(1):21-28. DOI: 10.1097/AOG.0000000000000018. View

17.

Tomson T, Battino D, Bonizzoni E, Craig J, Lindhout D, Perucca E . Withdrawal of valproic acid treatment during pregnancy and seizure outcome: Observations from EURAP. Epilepsia. 2016; 57(8):e173-7. DOI: 10.1111/epi.13437. View

18.

. Gynecologic Management of Adolescents and Young Women With Seizure Disorders: ACOG Committee Opinion, Number 806. Obstet Gynecol. 2020; 135(5):e213-e220. DOI: 10.1097/AOG.0000000000003827. View

19.

Sharma S, Chen Z, Rychkova M, Dunne J, Lee J, Lawn N . Risk factors and consequences of self-discontinuation of treatment by patients with newly diagnosed epilepsy. Epilepsy Behav. 2022; 131(Pt A):108664. DOI: 10.1016/j.yebeh.2022.108664. View

20.

Richardson J, Damkier P, Diav-Citrin O, George N, Greenall A, Oliver A . A critical appraisal of controlled studies investigating malformation risks following pregabalin use in early pregnancy. Br J Clin Pharmacol. 2022; 89(2):630-640. DOI: 10.1111/bcp.15607. View